Haleon Adjusts FY26 Organic Revenue Growth To ~2.5%, High-Single-Digit Adjusted Operating Profit Growth At Constant Currency, Net Interest Of ~£255 Million, Incorporating China Centrum OTC Product Classification Changes And Accelerated Brazil Go-To-Market Model Rollout
2026 Outlook The FY 2026 guidance incorporates the impact from the raw material classification change impacting Centrum OTC-registered products in China and an expected impact of the acceleration of our new go-to-market
Haleon lowered its growth forecast for next year to about 2.5% due to China rule changes and Brazil strategy shifts. When a company adjusts expectations downward, watch how customers and investors react over the next few weeks.
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only. Not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.